Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

In this page

Clinical Trial

NCT05536297 Active, Not recruiting
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
Phase 3
Interventional

Disease

Disease type

Geographic Atrophy

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

26/09/2022

Closing date

31/03/2023

Inclusion criteria :

More

Exclusion criteria :

More

Funding

private

Members involved

Others investigators

Dr Yannick Lemer

Representative

France

See more

Pr Martin Spitzer

Representative

Germany

Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Dr Johannes Birtel

Substitute

Germany

CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Dr Claudia Priglinger

Representative

Germany

See more

Pr Andreas Wedrich

Representative

Austria

See more

ERN EYE member investigating site

HCP : Principal investigators